Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

October 6, 2005

Primary Completion Date

March 15, 2008

Study Completion Date

March 15, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

lecozotan SR

"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."

DRUG

Donepezil

10 mg donepezil QD dosed up to 40 weeks

Trial Locations (56)

450

Gascon

1035

Larrea

1709

Florida

2077

Hornsby

2184

Calle Adolfo Alsina

2945

Av. Belgrano

3081

Heidelberg Heights

3356

Cervino

3952

Nueva York

4102

Puerto Galván

7500

Panorama

7530

Bellville

7925

Observatory

9301

Westdene

10312

Staten Island

11516

Cedarhurst

11559

Lawrence

12208

Albany

19107

Philadelphia

27103

Winston-Salem

32216

Jacksonville

32806

Orlando

33009

Hallandale

33016

Hialeah

33154

Miami Beach

33173

Miami

33176

Miami

33321

Fort Lauderdale

33407

West Palm Beach

33445

Delray Beach

33486

Boca Raton

33617

Tampa

33916

Fort Myers

34239

Sarasota

38119

Memphis

43210

Columbus

63104

St Louis

74104

Tulsa

77030

Houston

85013

Phoenix

85741

Tucson

92037

La Jolla

92626

Costa Mesa

92868

Orange

93720

Fresno

07740

Long Branch

08759

Manchester Twp.

02914

East Providence

05201

Bennington

Unknown

Pilar

Montreal

T5G 0B7

Edmonton

T1A 4C2

Medicine Hat

E1C 4B7

Moncton

K1N 5C8

Ottawa

S4T 1A5

Regina

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00151398 - Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter